Ovoca Bio PLC
LSE:OVB

Watchlist Manager
Ovoca Bio PLC Logo
Ovoca Bio PLC
LSE:OVB
Watchlist
Price: 1.15 GBX Market Closed
Market Cap: 1m GBX

Ovoca Bio PLC
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ovoca Bio PLC
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Ovoca Bio PLC
LSE:OVB
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Gross Profit
$1.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
-2%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Gross Profit
$3.7B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
12%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Gross Profit
$226.4m
CAGR 3-Years
N/A
CAGR 5-Years
55%
CAGR 10-Years
6%
Cosmo Pharmaceuticals NV
SIX:COPN
Gross Profit
€134.5m
CAGR 3-Years
48%
CAGR 5-Years
27%
CAGR 10-Years
14%
No Stocks Found

Ovoca Bio PLC
Glance View

Market Cap
1m GBX
Industry
Pharmaceuticals

Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.

OVB Intrinsic Value
2.48 GBX
Undervaluation 54%
Intrinsic Value
Price

See Also

Back to Top